- Home
- NUWE vs TOVX Comparison
NUWE vs TOVX Comparison
Compare NUWE & TOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUWE
- TOVX
- Stock Information
- Founded
- NUWE 1999
- TOVX 2001
- Country
- NUWE United States
- TOVX United States
- Employees
- NUWE N/A
- TOVX N/A
- Industry
- NUWE Biotechnology: Electromedical & Electrotherapeutic Apparatus
- TOVX Biotechnology: Pharmaceutical Preparations
- Sector
- NUWE Health Care
- TOVX Health Care
- Exchange
- NUWE Nasdaq
- TOVX Nasdaq
- Market Cap
- NUWE 3.9M
- TOVX 4.5M
- IPO Year
- NUWE N/A
- TOVX 2006
- Fundamental
- Price
- NUWE $3.77
- TOVX $0.41
- Analyst Decision
- NUWE
- TOVX Hold
- Analyst Count
- NUWE 0
- TOVX 1
- Target Price
- NUWE N/A
- TOVX N/A
- AVG Volume (30 Days)
- NUWE 192.1K
- TOVX 359.6K
- Earning Date
- NUWE 11-10-2025
- TOVX 11-11-2025
- Dividend Yield
- NUWE N/A
- TOVX N/A
- EPS Growth
- NUWE N/A
- TOVX N/A
- EPS
- NUWE N/A
- TOVX N/A
- Revenue
- NUWE $8,318,000.00
- TOVX N/A
- Revenue This Year
- NUWE $6.53
- TOVX N/A
- Revenue Next Year
- NUWE $51.63
- TOVX N/A
- P/E Ratio
- NUWE N/A
- TOVX N/A
- Revenue Growth
- NUWE N/A
- TOVX N/A
- 52 Week Low
- NUWE $3.74
- TOVX $0.37
- 52 Week High
- NUWE $175.98
- TOVX $4.20
- Technical
- Relative Strength Index (RSI)
- NUWE 29.64
- TOVX 46.72
- Support Level
- NUWE $3.74
- TOVX $0.38
- Resistance Level
- NUWE $5.23
- TOVX $0.44
- Average True Range (ATR)
- NUWE 0.35
- TOVX 0.02
- MACD
- NUWE 0.12
- TOVX 0.00
- Stochastic Oscillator
- NUWE 7.59
- TOVX 44.29
About NUWE Nuwellis Inc.
Nuwellis Inc is a medical technology company focused on developing, manufacturing, and commercializing a medical device used in ultrafiltration therapy, including the Aquadex FlexFlow and the Aquadex SmartFlow systems. The Aquadex Smartflow System removes excess fluid from patients suffering from fluid overload who have not responded to medical management, including diuretics. Nuwellis has one reportable segment: fluid overload.
About TOVX Theriva Biologics Inc.
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.